Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma

被引:7
作者
Kim, J [1 ]
Logothetis, CJ [1 ]
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Oncol, Houston, TX 77030 USA
关键词
D O I
10.1016/S0094-0143(05)70068-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
This article attempts to address the dilemmas created by, and the challenges identified with, the use of the serum prostate-specific antigen (PSA) concentration in clinical practice. PSA has contributed to our understanding of the prevalence of prostate cancer, phenomena related to the androgen regulation of the cancer, and the accelerated development of therapies for hormone refractory prostate cancer. PSA, however, is of limited prognostic value in adrogen-independent prostate cancer. Future challenges remain in the development of serologic tumor markers that can predict virulence of disease and reflect androgen-independent progression.
引用
收藏
页码:281 / +
页数:12
相关论文
共 103 条
[41]   PHASE-II STUDY OF ESTRAMUSTINE AND VINBLASTINE, 2 MICROTUBULE INHIBITORS, IN HORMONE-REFRACTORY PROSTATE-CANCER [J].
HUDES, GR ;
GREENBERG, R ;
KRIGEL, RL ;
FOX, S ;
SCHER, R ;
LITWIN, S ;
WATTS, P ;
SPEICHER, L ;
TEW, K ;
COMIS, R .
JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (11) :1754-1761
[42]   Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer [J].
Hudes, GR ;
Nathan, F ;
Khater, C ;
Haas, N ;
Cornfield, M ;
Giantonio, B ;
Greenberg, R ;
Gomella, L ;
Litwin, S ;
Ross, E ;
Roethke, S ;
McAleer, C .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (09) :3156-3163
[43]  
Huggins C, 1941, CANCER RES, V1, P293
[44]  
ISAACS JT, 1981, CANCER RES, V41, P5070
[45]   ARGENTAFFIN AND ARGYROPHIL CELLS IN PROSTATE [J].
KAZZAZ, BA .
JOURNAL OF PATHOLOGY, 1974, 112 (03) :189-+
[46]   PROSPECTIVE EVALUATION OF HYDROCORTISONE AND SURAMIN IN PATIENTS WITH ANDROGEN-INDEPENDENT PROSTATE-CANCER [J].
KELLY, WK ;
CURLEY, T ;
LEIBERTZ, C ;
DNISTRIAN, A ;
SCHWARTZ, M ;
SCHER, HI .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (09) :2208-2213
[47]  
KELLY WK, 1993, J UROLOGY, V149, P607
[48]   PROSTATE-SPECIFIC ANTIGEN AS A MEASURE OF DISEASE OUTCOME IN METASTATIC HORMONE-REFRACTORY PROSTATE-CANCER [J].
KELLY, WK ;
SCHER, HI ;
MAZUMDAR, M ;
VLAMIS, V ;
SCHWARTZ, M ;
FOSSA, SD .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) :607-615
[49]  
KOZLOWSKI JM, 1991, UROL CLIN N AM, V18, P15
[50]   Cancer statistics, 1998 [J].
Landis, SH ;
Murray, T ;
Bolden, S ;
Wingo, PA .
CA-A CANCER JOURNAL FOR CLINICIANS, 1998, 48 (01) :6-+